المصري اليوم
المصري اليوم
Ready to play
Ready to play
An official from the Egyptian Drug Authority denied the accuracy of reports suggesting approval to reprice and increase the prices of 40 pharmaceutical products starting next January. He confirmed that the applications submitted by pharmaceutical companies are currently under review and evaluation to assess the extent to which costs impact prices. He explained that the authority rejected approximately 90% of the requests to raise prices and that all applications are carefully examined before any decision is made. He also indicated that there is no current plan to raise prices until the end of 2026, and that any potential increase would be linked to the results of the cost review.
Notice: This Is an AI-Generated Summary
Comments (0)